Relationship between survival to breast cancer and level of HER2 expression by immunohistochemistry

Autor:	Brigitte Poirier, Catherine Doyle, Louise Provencher, Julie Lemieux, Caroline Diorio, Ion Popa, Jean-Charles Hogue, Éric Poirier, Isabelle Gagné, Christine Desbiens, Dominique K. Boudreau
Rok vydání:	2017
Předmět:	Oncology Cancer Research Pathology medicine.medical_specialty Her2 expression business.industry medicine.disease Breast cancer Trastuzumab Internal medicine Medicine Immunohistochemistry skin and connective tissue diseases business medicine.drug
Zdroj:	Journal of Clinical Oncology. 35:e13078-e13078
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2017.35.15_suppl.e13078
Popis:	e13078 Background: Central review of NSABP B-31 showed that some central-review HER2-negative patients benefited from trastuzumab, but survival according to different levels of HER2 expression by immunohistochemistry (IHC) is unknown. The aim of the present study was to examine the survival of trastuzumab-naïve patients with breast cancer according to the level of HER2 expression by IHC. Methods: This was a retrospective study of all women who were treated for an invasive breast cancer at the Centre des maladies du Sein Deschênes-Fabia (Quebec City, Province of Quebec, Canada) between July 1999 and December 2010. Patients were grouped according to the HER2 status by IHC of their primary cancer (0 vs. 1+ vs. 2+ vs. 3+). Survival was obtained from the death registry of the Ministry of Health. Follow-up was censored on December 31st, 2012. Results: During the study period, 2571 patients with invasive breast cancer, with available HER2 status by IHC and survival data, and naïve to anti-HER2 therapy were treated at our center. Both 5- and 9-year overall survival (OS) decreased with increasing HER2 expression by IHC (9-year OS: 0: 86.2% vs. 1+: 71.3% vs. 2+: 73.9% vs. 3+: 69.3%; unadjusted log-rank test: P < 0.0001; adjusted P = 0.04 for 3+). Both 5- and 9-year breast cancer-specific survival (BCSS) decreased with increasing HER2 expression by IHC (9-year BCSS: 0: 90.7% vs. 1+: 81.8% vs. 2+: 77.0% vs. 3+: 75.4%; unadjusted log-rank test: P < 0.0001; adjusted P = 0.04 for 3+). Conclusions: Survival among trastuzumab-naïve breast cancer patients seems to follow a continuum across HER2 expression by IHC.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::21ac70f3b3cf6d26b152722556068e7a https://doi.org/10.1200/jco.2017.35.15_suppl.e13078 Zobrazit plný text záznamu